Novonesis stock trades at DKK 424.80 as buyback begins

Published on 09/29/2026 at 07:01 | Editorial responsibility: Rafael Müller, Editor-in-Chief AD HOC NEWS

Novonesis stock enters a EUR 75 million first buyback tranche launched on September 28, 2026. H1 organic sales grew 8 percent and adjusted EBITDA margin reached 37.7 percent.

Industrieanlage mit Fermentationstanks eines daenischen Biotech-Unternehmens — Fotorealistische Ansicht einer Biotech-Anlage von Novonesis (Novozymes), ISIN DK0060336014, mit modernen Fermentationstanks in Bagsvaerd, Illustration mit AI erstellt.

Novonesis stock was last at DKK 424.80 on Nasdaq Copenhagen on September 28, 2026 at 5:00 p.m. CEST, down DKK 1.90 or 0.45 percent from the prior close. The company began the first tranche of its multi-year share buyback program on the same date, giving the market a fresh capital-allocation signal.

Buyback starts with EUR 75 million

According to Nasdaq on September 28, 2026, the first tranche can reach EUR 75 million and is scheduled to end no later than December 17, 2026. The broader program totals EUR 1 billion and is expected to run through 2029, while the shares acquired in this tranche will support employee incentive obligations.

The buyback follows a stronger first half. It also leaves room for Novonesis to keep investing in production capacity and pursue bolt-on acquisitions, according to management's H1 conference call.

H1 growth supports guidance

In the H1 2026 conference call, Yahoo Finance reported that Novonesis delivered 8 percent organic sales growth and a 37.7 percent adjusted EBITDA margin in the first half of 2026. The margin improved from 37.4 percent in the comparable period, while adjusted earnings per share increased 9 percent year over year to EUR 1.09.

Management raised full-year organic sales growth guidance to 7-8 percent and expects adjusted EBITDA margin at the high end of the 37-38 percent range. The main counterweight is a softer second half in human health, while the company also expects 2026 capital expenditure at 12-14 percent of sales.

Stock stays below yearly high

Novonesis stock remained 8.65 percent below its 52-week high of DKK 465.00 on September 28, 2026. The same session showed a low of DKK 418.30, a high of DKK 430.40 and volume of 204,521 shares, while market capitalization stood at DKK 118.1 billion.

MarketScreener lists November 4, 2026 as the scheduled Q3 2026 earnings release. For investors, the next test is whether the buyback and H1 growth can offset the tougher second-half comparisons already reflected in the outlook.